Introduction:
Trastuzumab and lapatinib are standard of care in HER-2 positive breast Ca, with superior efficacy in this subgroup of patients. Previous studies revealed lack of complete cross-resistance of lapatinib with trastuzumab, modest activity in brain metastases and relatively low rates of cardiotoxicity. In a phase 1 trial, lapatinib with trastuzumab provided clinical responses with tolerable toxicity in heavily pre-treated HER-2 positive breast Ca (J Clin Oncol 26:3317-3323, 2008) . Researchers conducted a head-to-head comparison of lapatinib and trastuzumab alone or in combination in HER-2 positive breast Ca in the adjuvant setting.
Methods:
• Patients: completely excised invasive nonmetastatic HER2-positive breast cancer, either node positive or node negative with tumor ≥1 cm
• Trial design: phase III, open-label RCT
• Intervention: 1. Trastuzumab 4mg/kg LD then 2mg/kg weekly during chemo or 8mg/kg LD then 6 mg/kg q3w alone 2. Lapatinib 750mg/d during chemo and 1,500 mg/day alone 3. Trastuzumab 12 weekly doses, 6 wk. washout then Lapatinib 1,500 mg/d x 34 wks. 4. Trastuzumab (same dose as treatment 1) with Lapatinib 1,000 mg/d Treatment designs 1. Anti-HER2 agents administered after chemo (neoadjuvant/adjuvant chemo completed prior to randomization) 2. Anthracycline prior to randomization then anti-HER 2 agents given concomitantly with taxane (docetaxel/paclitaxel) 2B. Non-anthracycline (docetaxel with carboplatin x 12 cycles) given concomitantly with anti-HER2 agents All treatment arms administered targeted therapy for 1 yr. All hormone-positive patients received endocrine treatment, unless contraindicated; RT was mandatory for BCS.
• Endpoints: Primary: DFS Secondary: OS, safety, time to recurrence, time to distant recurrence, time to first brain mets
Results:
• 8,381 randomised and analyzed by ITT; L+T n=2,093, T→L n=2,091, L n=2,100, T n=2,097
• Baseline patient characteristics: median age 51 yrs. (range 18-82), 10% ≥ 65 yrs., 40% node negative, 41% with tumors ≤ 2 cm, 57% hormone positive (89% received endocrine therapy)
• 92% (across all arms) received ≥ 85% of planned dose for T; 66% to 76% received ≥ 85% of planned dose of L
Safety
• Higher rates of AEs with L-containing arm (especially diarrhea) but mostly grade 1-2) vs. T arm; median duration of diarrhea: 25 days
• Most common AE's with L leading to dose continuations/interruptions/delays: diarrhea, rash, neutropenia
• Skin toxicity: 50% (L-containing arm) v 20% (T arm) but mostly grade 1-2, with longest median time to onset in T→L arm (135 days); 99% resolved, 1-3% led to treatment discontinuation
• Hepatobiliary events mostly grade 1-2 were higher in L-containing arms; fatal hepatobiliary toxicity was observed in one patient in L arm and two in T→L arm
• 47 fatal AEs reported: 31 (Design 1), 14 (design 2), 2 (design 2B
• Cardiac toxicity observed in 0.25-0.97%; three fatal cardiac events in T→L arm and one in each of the other arms
• <1% incidence of interstitial pneumonitis and febrile neutropenia (across all arms)
• SAE rates higher in L-containing arms especially with concomitant chemo 88 (4) 95 (5) 140 (7) 112 ( • 1,087 (52%) out of 2,100 in the L arm received at least one dose of T prior to a DFS event.
Efficacy (L+T v T and T→ L v T)
• Incidence of CNS as first relapse: 2% in all treatment arms Discussion:
• Trastuzumab in combination with lapatinib was not superior to trastuzumab as adjuvant treatment in HER-2 positive breast Ca. The 16% reduction in hazard for DFS at a median follow-up of 4.5 yrs. was not statistically significant. Trastuzumab followed by lapatinib failed to demonstrate noninferiority vs. trastuzumab.
• Lapatinib-containing arms had higher toxicity rates compared with trastuzumab arm, in particular diarrhea (15% L+T arm). Treatment withdrawals due to AEs occurred in 13-23% in lapatinib-containing arms compared with 8% with trastuzumab.
• Lapatinib arm was closed due to worse DFS rates compared with trastuzumab Patients who received trastuzumab in this arm achieved 33% reduction in DFS hazard rate (post hoc analysis).
• Rates of cardiac toxicity were low (<1%) across all arms and for both anti-HER2 agents. Hepatotoxicity rates were higher in lapatinib-containing arms but were mostly grade 1-2. Three deaths were related to hepatotoxicity.
• Findings in this study are consistent with emerging data from trials that suggest inferiority of lapatinib compared with trastuzumab. • ALTTO trial revealed that combining two anti-HER2 agents (lapatinib with trastuzumab) did not confer additional benefit over standard of care (trastuzumab) when given in combination with chemotherapy (concomitantly or sequentially) in early HER2-positive breast Ca. Noninferiority of sequential trastuzumab followed by lapatinib compared with trastuzumab was not demonstrated in this study. Lapatinib was associated with higher rates of AEs compared with trastuzumab. These findings support current guidelines recommending one year of adjuvant trastuzumab in combination with chemotherapy in this breast Ca subgroup.
